References
- IronsJFluvoxamine in the treatment of anxiety disordersNeuropsychiatr Dis Treat20051428929918568110
- BandelowBZoharJHollanderEWFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Post-Traumatic Stress DisordersWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revisionWorld J Biol Psychiatry20089424831218949648
- PollackMHLepolaUKoponenHA double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorderDepress Anxiety200724111416894619
- MillanMJMulti-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic applicationPharmacol Ther2006110213517016522330
- FurukawaTAAkechiTShimoderaSStrategic use of new generation antidepressants for depression: SUN(^_^)D study protocolTrials20111211621569309
- PapakostasGIManaging partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorderJ Clin Psychiatry200970Suppl 6162519922740
- MoretCCombination/augmentation strategies for improving the treatment of depressionNeuropsychiatr Dis Treat20051430130918568111
- PallantiSQuercioliLBruscoliMResponse acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot studyJ Clin Psychiatry200465101394139915491244
- YamauchiMImanishiTKoyamaTA combination of mirtazapine and milnacipran augments the extracellular levels of monoamines in the rat brainNeuropharmacology20126272278228722342987
- ErikksonEHumbleMSerotonin in psychiatric pathophysiology. A review of data from experimental and clinical researchPohlRGershonSProgress in Basic Clinical PharmacologyBaselKarger1990366119
- InoueTKitaichiYKoyamaTSSRIs and conditioned fearProg Neuropsychopharmacol Biol Psychiatry20113581810181921925230
- KakuiNYokoyamaFYamauchiMAnxiolytic-like profile of mirtazapine in rat conditioned fear stress model: Functional significance of 5-hydroxytryptamine 1A receptor and alpha1-adrenergic receptorPharmacol Biochem Behav200992339339819167420
- PertovaaraAHaapalinnaASirviöJVirtanenRPharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective alpha2-adrenoceptor antagonistCNS Drug Rev200511327328816389294
- HaapalinnaAViitamaaTMacDonaldEEvaluation of the effects of a specific alpha 2-adrenoceptor antagonist, atipamezole, on alpha 1-and alpha 2-adrenoceptor subtype binding, brain neurochemistry and behaviour in comparison with yohimbineNaunyn Schmiedebergs Arch Pharmacol199735655705829402036
- GobertARivetJMCistarelliLMelonCMillanMJAlpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving ratsJ Neurochem1997696261626199375697
- InoueTLiXBAbekawaTSelective serotonin reuptake inhibitor reduces conditioned fear through its effect in the amygdalaEur J Pharmacol2004497331131615336949
- MurakiIInoueTKoyamaTEffect of co-administration of the selective 5-HT1A receptor antagonist WAY 100,635 and selective 5-HT1B/1D receptor antagonist GR 127,935 on anxiolytic effect of citalopram in conditioned fear stress in the ratEur J Pharmacol20085861–317117818423441
- HashimotoSInoueTKoyamaTSerotonin reuptake inhibitors reduce conditioned fear stress-induced freezing behavior in ratsPsychopharmacology (Berl)199612321821868741941
- de BoerTHNefkensFvan HelvoirtAvan DelftAMDifferences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxanJ Pharmacol Exp Ther199627728528608627567
- BengtssonHJKeleJJohanssonJHjorthSInteraction of the antidepressant mirtazapine with alpha2-adrenoceptors modulating the release of 5-HT in different rat brain regions in vivoNaunyn Schmiedebergs Arch Pharmacol20003624–540641211111835
- MillanMJGobertARivetJMMirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopramEur J Neurosci20001231079109510762339
- MuellerDOlivera-FigueroaLAPineDSQuirkGJThe effects of yohimbine and amphetamine on fear expression and extinction in ratsPsychopharmacology (Berl)2009204459960619242678